IPCA Laboratories Share Price Today | Stock Price & IPCA Laboratories Share Screener
As of November 19, 2026, the live IPCA Laboratories share price (NSE: IPCALAB) is ₹1,860.00 on NSE and ₹1,859.75 on BSE, up 0.32% from the previous close, with shares trading between ₹1,845.10 and ₹1,890.50 in today's trading session, and a 52-week range of ₹1,385.80–₹2,009.60. Track IPCALAB market value to gauge the company's total market size. Use the IPCA Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today IPCA Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹2,482 and net income of ₹307, with EBITDA of ₹532, an operating margin of 18.0% and a profit margin of 12.4%.
IPCA Laboratories Share Price Chart
Track the current stock price of IPCA Laboratories with an interactive chart. Analyse IPCALAB share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete IPCA Laboratories stock quote in one place.
The quote of ₹1,860.00 sits between the 52-week low of ₹1,385.80 and the 52-week high of ₹2,009.60, and the latest session moved 0.32% from the previous close.
IPCA Laboratories Company Profile - Fundamental Screener
Screen IPCA Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for IPCALAB shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Premchand Godha listed as chairperson or CEO, and it trades under ISIN INE571A01038.
Business Overview
Ipca Laboratories Limited is an Indian integrated pharmaceutical company that manufactures and markets over 350 formulations and 80 active pharmaceutical ingredients (APIs) across various therapeutic segments. The company operates 18 manufacturing units in India and sells its products in over 100 countries worldwide. Ipca specializes in producing APIs such as...more
Company Details
Classification
Identifiers and Leadership
IPCA Laboratories Balance Sheet Screener
Screen IPCALAB balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹12,370, up from ₹11,761 in 2025.
Latest statistics put total assets at ₹12,370 and shareholder funds at ₹9,524, with a leverage ratio of 0.14.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 12,370 | 11,761 | 11,101 | 8,626 | 7,639 | 6,068 | 5,260 | 4,551 | 4,117 | 3,960 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 4,627 | 4,267 | 4,553 | 2,751 | 2,418 | 2,072 | 2,059 | 1,940 | 1,953 | 1,983 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 539 | 986 | 1,019 | 905 | 604 | 192 | 292 | 315 | 421 | 548 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 9,524 | 8,388 | 7,727 | 5,915 | 5,569 | 4,716 | 3,641 | 3,138 | 2,689 | 2,455 |
| Share Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| Reserves & Surplus | 8,038 | 6,923 | 6,307 | 5,817 | 5,467 | 4,676 | 3,590 | 3,097 | 2,663 | 2,430 |
IPCA Laboratories Income Statement Screener - Profit & Revenue Analysis
Screen IPCA Laboratories income statement and profit fundamentals. Analyze IPCALAB quarterly results. IPCA Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2026-Mar, revenue was ₹2,482 and net profit was ₹307, equal to earnings per unit of ₹13.31, at an operating margin of 18%.
In that period expenses were ₹1,950, interest cost ₹20 and tax ₹98. The next period listed, 2026-Jun, shows revenue of ₹2,813 and net profit of ₹424.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 2,482 | 2,813 | 2,935 | 2,273 | 2,342 | 2,584 | 2,430 | 2,052 | 2,113 | 2,381 | 2,266 | 1,548 | 1,630 | 2,073 | 2,144 |
| Expenses | 1,950 | 2,119 | 2,261 | 2,023 | 1,892 | 2,070 | 1,859 | 1,848 | 1,700 | 1,913 | 1,782 | 1,331 | 1,278 | 1,713 | 1,722 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 532 | 695 | 674 | 250 | 449 | 515 | 571 | 204 | 413 | 468 | 483 | 217 | 353 | 360 | 422 |
| Operating Profit % | 18.00% | 24.00% | 22.00% | 10.00% | 18.00% | 19.00% | 22.00% | 9.00% | 19.00% | 19.00% | 21.00% | 12.00% | 19.00% | 16.00% | 16.00% |
| Depreciation | 107 | 111 | 115 | 100 | 100 | 103 | 108 | 98 | 99 | 100 | 99 | 70 | 69 | 90 | 100 |
| Interest | 20 | 12 | 13 | 22 | 19 | 20 | 18 | 29 | 24 | 23 | 17 | 19 | 31 | 44 | 33 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 405 | 572 | 547 | 128 | 331 | 392 | 446 | 77 | 290 | 345 | 368 | 129 | 252 | 225 | 289 |
| Tax | 98 | 148 | 158 | 64 | 98 | 111 | 82 | 75 | 91 | 99 | 92 | 51 | 88 | 89 | 68 |
| Net Profit | 307 | 424 | 389 | 64 | 233 | 281 | 364 | 1 | 199 | 246 | 276 | 78 | 164 | 137 | 221 |
| EPS | 13.31 | 15.84 | 14.79 | 2.67 | 9.19 | 11.14 | 12.86 | 2.35 | 7.58 | 9.05 | 9.78 | 3.02 | 6.42 | 5.72 | 7.09 |
IPCA Laboratories Cash Flow Screener - Liquidity Fundamentals
Screen IPCALAB cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹1,142, and net cash flow was an inflow of ₹142.
Over the same period, investing activities used ₹247 and financing activities used ₹754.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 1,142 | 1,321 | 945 | 806 | 856 | 1,090 | 570 | 501 | 341 | 282 |
| Investing Activities | -247 | -870 | -1,215 | -725 | -851 | -521 | -509 | -165 | -135 | -149 |
Financing and Net Cash | ||||||||||
| Financing Activities | -754 | -283 | -553 | 507 | 427 | -306 | -137 | -183 | -130 | -159 |
| Net Cash Flow | 142 | 169 | -823 | 588 | 432 | 264 | -76 | 153 | 75 | -26 |
IPCA Laboratories Shareholding Pattern Screener
See IPCA Laboratories shareholding pattern with promoter, FII, and DII holdings. Check IPCA Laboratories promoter holding and ownership changes for IPCALAB on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Sept, promoters held 44.72%, foreign institutions 11.53%, domestic institutions 36.59% and the public 5.72%, spread across 90,514 shareholders.
The shareholder count was 90,514 in 2026-Sept, compared with 82,060 in 2026-Jun.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% | 44.72% |
Institutional Investors | ||||||||
| FII Holding | 11.53% | 10.73% | 10.63% | 10.63% | 10.43% | 10.67% | 10.76% | 11.07% |
| DII Holding | 36.59% | 37.37% | 37.45% | 37.32% | 36.77% | 36.20% | 36.06% | 35.68% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 5.72% | 5.76% | 5.79% | 5.88% | 6.55% | 6.82% | 6.81% | 6.88% |
| Other Holding | 1.43% | 1.42% | 1.41% | 1.44% | 1.53% | 1.59% | 1.65% | 1.65% |
| Shareholder Count | 90,514 | 82,060 | 82,184 | 77,673 | 82,870 | 85,582 | 88,306 | 90,189 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by IPCA Laboratories. IPCA Laboratories dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹4.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹4.00 and ₹4.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹4.00 | 0.25% |
| 2024-March | ₹4.00 | 0.27% |
| 2023-March | ₹4.00 | 0.32% |
| 2022-March | ₹8.00 | 1.02% |
| 2021-March | ₹8.00 | 0.75% |
| 2020-March | ₹5.00 | 0.53% |
| 2019-March | ₹3.00 | 0.43% |
| 2018-March | ₹1.00 | 0.20% |
| 2017-March | ₹1.00 | 0.31% |
IPCA Laboratories Stock Index Membership - Nifty & Sensex
See which indices include IPCA Laboratories stock. Check IPCALAB index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 22 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE 200 EQUAL WEIGHT, BSE INDEX BSE HC, BSE INDEX BSE200.
Complete Index List
IPCA Laboratories Market Events Screener - Corporate Actions
Get IPCA Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check IPCA Laboratories stock events that may affect IPCALAB share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 5, 2026, with a record date of November 5, 2026.
It is followed by Quarterly Result Announcement dated August 13, 2026 and Annual General Meeting dated August 13, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-05 | 2026-11-05 | Quarterly Result Announcement | NA | 2.77% |
| 2026-08-13 | 2026-08-13 | Quarterly Result Announcement | NA | -0.59% |
| 2026-08-13 | 2026-08-13 | Annual General Meeting | NA | -1.19% |
| 2026-08-07 | 2026-08-07 | Dividend | ₹ 6.00 /share | 10.24% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 2.71% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | -0.54% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 4.12% |
| 2025-08-11 | 2025-08-11 | Quarterly Result Announcement | NA | -5.30% |
| 2025-08-11 | 2025-08-11 | Annual General Meeting | NA | -4.14% |
| 2025-08-05 | 2025-08-05 | Dividend | ₹ 2.00 /share | -3.58% |
| 2025-05-29 | 2025-05-29 | Quarterly Result Announcement | NA | 6.52% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -6.28% |
| 2024-11-27 | 2024-11-27 | Dividend | ₹ 2.00 /share | 3.99% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -3.83% |
| 2024-08-13 | 2024-08-13 | Annual General Meeting | NA | 13.43% |
IPCA Laboratories Competitors Screener - Peer Stocks Comparison
Screen IPCALAB competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 451,075 | 41.20 | 61,674 | 12.69% | 11,565 | 63.60 |
| Divis Laboratories | 303,749 | 90.40 | 11,067 | 13.95% | 2,568 | 78.53 |
| Torrent Pharmaceuticals | 177,632 | 85.50 | 13,886 | 20.34% | 2,138 | 47.27 |
| Laurus Labs | 130,972 | 97.10 | 6,868 | 22.01% | 890 | 69.60 |
| Zydus Life Science | 118,693 | 28.00 | 27,658 | 17.64% | 5,026 | 52.34 |
| Dr Reddys Laboratories | 115,186 | 42.00 | 35,059 | 3.90% | 4,158 | 70.24 |
| Cipla | 112,438 | 39.90 | 29,045 | 2.24% | 3,870 | 54.92 |
| Mankind Pharma | 109,044 | 48.10 | 14,636 | 14.85% | 1,938 | 65.43 |
| Aurobindo Pharma | 104,903 | 26.00 | 34,145 | 5.56% | 3,503 | 66.06 |
| Lupin | 90,557 | 17.60 | 29,039 | 26.75% | 5,356 | 44.92 |
IPCA Laboratories Company Announcements - News & Reports Screener
Screen IPCALAB latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 11, 2026.
The next most recent announcements are dated November 11, 2026 and November 10, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-11 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-11-11 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-11-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-11-10 | Standalone And Consolidated Financial Results For Second Quarter And Half Year Ended 30.09.2026 | - |
| 2026-11-10 | Board Meeting Outcome for Standalone And Consolidated Financial Results For Second Quarter And Half Year Ended 30.09.2026 | - |
| 2026-10-28 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-10-22 | Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For The Second Quarter And Half Year Ended 30.09.2026 | - |
| 2026-10-12 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-09-22 | Closure of Trading Window | - |
| 2026-08-17 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-14 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-08-13 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-08-13 | Standalone And Consolidated Unaudited Financial Results For Q1FY27 | - |
| 2026-08-13 | Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results For Q1FY27 | - |
| 2026-08-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-07-28 | Board Meeting Intimation for Standalone And Consolidated Financial Results For 1St Quarter Ended 30Th June 2026 | - |
| 2026-07-17 | Intimation Of Web Link To Non-Email Cases | - |
| 2026-07-15 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹1,860.00, within a 52-week range of ₹1,385.80 to ₹2,009.60. The P/E ratio is 32.50 and the P/B ratio is 5.56, with earnings per unit of ₹44.98. Market capitalisation stands at ₹47,797.87 Cr and the dividend yield is 0.32%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.